{"protocolSection":{"identificationModule":{"nctId":"NCT02576574","orgStudyIdInfo":{"id":"EMR 100070-005"},"secondaryIdInfos":[{"id":"2015-001537-24","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"EMD Serono","class":"INDUSTRY"},"briefTitle":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","officialTitle":"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-10-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-12-06","type":"ACTUAL"},"completionDateStruct":{"date":"2024-01-29","type":"ACTUAL"},"studyFirstSubmitDate":"2015-10-13","studyFirstSubmitQcDate":"2015-10-14","studyFirstPostDateStruct":{"date":"2015-10-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-11-07","resultsFirstSubmitQcDate":"2022-12-09","resultsFirstPostDateStruct":{"date":"2023-01-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-20","lastUpdatePostDateStruct":{"date":"2025-01-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"EMD Serono Research & Development Institute, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors."},"conditionsModule":{"conditions":["First Line Non-Small Cell Lung Cancer"],"keywords":["Avelumab","MSB0010718C","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1214,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Avelumab Biweekly","type":"EXPERIMENTAL","interventionNames":["Drug: Avelumab"]},{"label":"Avelumab Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Drug: Avelumab Weekly"]},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pemetrexed","Drug: Paclitaxel","Drug: Gemcitabine","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Avelumab","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab Biweekly"],"otherNames":["Anti-PD-L1","MSB0010718C"]},{"type":"DRUG","name":"Pemetrexed","description":"Participants received Pemetrexed 500 milligrams per square meter (mg/m\\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Paclitaxel","description":"Participants received Paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine","description":"Participants received Gemcitabine 1250 mg/m\\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine","description":"Participants received Gemcitabine 1000 mg/m\\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Carboplatin","description":"Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Cisplatin","description":"Participants received Cisplatin 75 mg/m\\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab Weekly"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin AUC 6 mg/mL\\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.","armGroupLabels":["Chemotherapy"]},{"type":"DRUG","name":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.","armGroupLabels":["Avelumab Weekly"],"otherNames":["Anti-PD-L1","MSB0010718C"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Overall Survival (OS) in Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment","description":"EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.","timeFrame":"Baseline, End of treatment (up to Week 283.9)"},{"measure":"Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.","timeFrame":"Baseline, End of treatment (Week 283.9)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","timeFrame":"Baseline, End of treatment (up to Week 283.9)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","timeFrame":"Baseline, End of treatment (Week 283.9)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set","description":"EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).","timeFrame":"Baseline, End of treatment (up to Week 283.9)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).","timeFrame":"Baseline, End of treatment (up to Week 283.9)"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs)","description":"Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAEs were those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period TEAEs included both serious TEAEs and non-serious TEAEs. Any AE that was suspicious to be a potential Immune-related adverse event (irAE) including infusion related reactions were considered AESIs. Number of participants with TEAEs and AESIs were reported.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03","description":"Number of participants with shifts from Baseline values (Grade 0/1/2/3) to abnormal post-baseline values (shift to \\>= Grade 4) were reported as per NCI-CTCAE, v4.03 graded from Grade 1 to 5. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death. Shifts in laboratory parameter (anemia, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, white blood cell count decreased, alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased and Hyperglycemia) were reported.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase","description":"The number of participants with changes from baseline in increased Body Temperature (degree Celsius \\[°C\\]) were reported by using criteria: Baseline temperature (temp.) less than (\\<) 37°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, greater than or equal to (\\>=)3°C and missing; Baseline temp. 37 - \\<38°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. 38 - \\<39°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. 39-\\<40°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. \\>=40°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. missing, on treatment change missing.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease","description":"The number of participants with maximal on-treatment changes from baseline in Increase (Ic.)/Decrease (Dc.) in maximal weight were reported by using criteria: Ic./Dc. From baseline, on treatment (TR) change \\<10 percentage (%), \\>=10% and missing.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease","description":"The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) heart rate (HR) (beats per minute \\[bpm\\]) were reported by using criteria: Ic./Dc. BS HR \\<100/\\>=100 bpm, on treatment change =\\<20 bpm, \\>20 - =\\<40 bpm, \\>40 bpm and missing; Ic./Dc. BS HR missing, on treatment change missing.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease","description":"The number of participants with maximal on-treatment changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) Systolic Blood Pressure (SBP) and diastolic blood pressure (DBP) (millimeter of mercury \\[mmHg\\]) were reported by using criteria: Ic./Dc. BS SBP \\<140 mmHg and \\>=140 mmHg, on maximal treatment (TR) change =\\<20 mmHg, \\>20 - =\\<40 mmHg, \\>40 mmHg and missing; Ic./Dc. BS SBP missing, on maximal treatment (TR) change missing; Ic./Dc. BS DBP \\<90 mmHg and \\>= 90 mmHg, on maximal TR change =\\<20 mmHg, \\>20 - =\\<40 mmHg, \\>40 mmHg and missing; Ic./Dc. BS DBP missing on maximal TR change missing.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease","description":"The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) maximal Respiration Rate (RR) were reported by using criteria: Ic./Dc. BS RR \\<20 breaths per minute (breaths/min), on TR change =\\<5 breaths/min, \\>5 - =\\<10 breaths/min, \\>10 breaths/min and missing. Ic./Dc. BS RR missing, on TR change missing. Ic./Dc. BS RR \\>=20 breaths/min, on TR change =\\<5 breaths/min, \\>5 - =\\<10 breaths/min, \\>10 breaths/min and missing.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to 71.5 months)"},{"measure":"Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters","description":"ECG parameters included heart rate, PR interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). PCSA criteria for abnormal value of ECG parameters: any heart rate \\<= 50 bpm and decrease from baseline \\>=20 bpm , any hear rate \\>= 120 bpm and increase from baseline \\>= 20 bpm; PR interval: \\>= 220 milliseconds (ms) and increase from baseline \\>= 20 ms; QRS interval \\>= 120 ms; QTcF \\> 450 ms, \\> 480 ms, \\> 500 ms, QTcF increase from baseline \\> 30 ms and QTcF increase from baseline \\> 60 ms; QTcB \\> 450 ms, \\> 480 ms, \\> 500 ms, QTcB increase from baseline \\> 30 ms and QTcB increase from baseline \\> 60 ms.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score","description":"ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with baseline value vs worst post-baseline value (that is \\[i.e.\\] highest score).","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"},{"measure":"Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab","description":"Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay were tested for neutralizing antibodies (nAb). Number of participants with ADA or nAb positive results for Avelumab were reported.","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects aged greater than or equal to (\\>=) 18 years\n* With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry\n* At least 1 measurable tumor lesion\n* With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung cancer (NSCLC)\n* With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE) tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6 months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1 week, and suitable for PD-L1 expression assessment\n* Subjects must not have received any treatment for systemic lung cancer, and have an estimated life expectancy of more than 12 weeks\n* Other protocol defined criteria could apply\n\nExclusion Criteria:\n\n* Subjects whose disease harbors a EGFR mutation, or anaplastic lymphoma kinase (ALK) rearrangement are not eligible.\n* Other exclusion criteria include prior therapy with any antibody or drug targeting T cell coregulatory proteins, concurrent anticancer treatment, or immunosuppressive agents\n* Known severe hypersensitivity reactions to monoclonal antibodies (Grade \\>= 3 NCI CTCAE v 4.03), history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma), and persisting toxicity related to prior therapy of Grade \\> 1 NCI-CTCAE v 4.03.\n* Subjects with brain metastases are excluded, except those meeting the following criteria: brain metastases that have been treated locally and are clinically stable for at least 2 weeks prior to randomization, subjects must be either off steroids or on a stable or decreasing dose of \\<= 10 mg daily prednisone (or equivalent), and do not have ongoing neurological symptoms that are related to the brain localization of the disease.\n* Other protocol defined criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Responsible","affiliation":"EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clearview Cancer Institute","city":"Huntsville","state":"Alabama","zip":"35805","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Arizona Center for Cancer Care","city":"Surprise","state":"Arizona","zip":"85374","country":"United States","geoPoint":{"lat":33.63059,"lon":-112.33322}},{"facility":"Sharp Memorial Hospital","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"University Cancer Institute","city":"Boynton Beach","state":"Florida","zip":"33426","country":"United States","geoPoint":{"lat":26.52535,"lon":-80.06643}},{"facility":"South Georgia Medical Center","city":"Valdosta","state":"Georgia","zip":"31602","country":"United States","geoPoint":{"lat":30.83334,"lon":-83.28032}},{"facility":"Christus Cancer Treatment Center","city":"Shreveport","state":"Louisiana","zip":"71105","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Henry Ford Hospital","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"St. Vincent Frontier Cancer Center","city":"Billings","state":"Montana","zip":"59102","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Nevada Cancer Research Foundation","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"San Juan Oncology Associates","city":"Farmington","state":"New Mexico","zip":"87401","country":"United States","geoPoint":{"lat":36.72806,"lon":-108.21869}},{"facility":"Novant Health Oncology Specialists","city":"Kernersville","state":"North Carolina","zip":"27284","country":"United States","geoPoint":{"lat":36.11986,"lon":-80.07365}},{"facility":"Mercy Research","city":"Oklahoma City","state":"Oklahoma","zip":"73120","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Kaiser Permanente Northwest","city":"Portland","state":"Oregon","zip":"97227","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Lancaster Cancer Center","city":"Lancaster","state":"Pennsylvania","zip":"17605","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"Cookeville Regional Medical Center","city":"Cookeville","state":"Tennessee","zip":"38501","country":"United States","geoPoint":{"lat":36.16284,"lon":-85.50164}},{"facility":"Thompson Cancer Survival Center","city":"Knoxville","state":"Tennessee","zip":"37916","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Coastal Bend Cancer Center","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Oncology Consultants, P.A.","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Vermont Medical Center","city":"Burlington","state":"Vermont","zip":"05401-1473","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}},{"facility":"Northwest Medical Specialties, PLLC","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"Cheyenne Regional Medical Center","city":"Cheyenne","state":"Wyoming","zip":"82001","country":"United States","geoPoint":{"lat":41.13998,"lon":-104.82025}},{"facility":"Albury Wodonga Regional Cancer Centre","city":"Albury","state":"New South Wales","zip":"2640","country":"Australia","geoPoint":{"lat":-36.07482,"lon":146.92401}},{"facility":"Coffs Harbour Health Campus","city":"Coffs Harbour","state":"New South Wales","zip":"2450","country":"Australia","geoPoint":{"lat":-30.29626,"lon":153.11351}},{"facility":"St George Private Hospital","city":"Kogarah","state":"New South Wales","zip":"2217","country":"Australia","geoPoint":{"lat":-33.9681,"lon":151.13564}},{"facility":"Lismore Base Hospital","city":"Lismore","state":"New South Wales","zip":"2480","country":"Australia","geoPoint":{"lat":-28.81354,"lon":153.2773}},{"facility":"Orange Health Service","city":"Orange","state":"New South Wales","zip":"2800","country":"Australia","geoPoint":{"lat":-33.28397,"lon":149.10018}},{"facility":"Royal North Shore Hospital","city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Calvary Mater Newcastle","city":"Waratah","state":"New South Wales","zip":"2298","country":"Australia","geoPoint":{"lat":-32.90667,"lon":151.72647}},{"facility":"Gallipoli Medical Research Foundation Ltd","city":"Greenslopes","state":"Queensland","zip":"4120","country":"Australia","geoPoint":{"lat":-27.50815,"lon":153.04951}},{"facility":"Gold Coast University Hospital","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"The Queen Elizabeth Hospital","city":"Woodville South","state":"South Australia","zip":"5011","country":"Australia","geoPoint":{"lat":-34.88186,"lon":138.53477}},{"facility":"Ballarat Base Hospital","city":"Ballarat","state":"Victoria","zip":"3350","country":"Australia","geoPoint":{"lat":-37.56622,"lon":143.84957}},{"facility":"Bendigo Hospital","city":"Bendigo","state":"Victoria","zip":"3550","country":"Australia","geoPoint":{"lat":-36.75818,"lon":144.28024}},{"facility":"South West Healthcare","city":"Warrnambool","state":"Victoria","zip":"3280","country":"Australia","geoPoint":{"lat":-38.38176,"lon":142.48799}},{"facility":"Fiona Stanley Hospital","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"ZNA Middelheim","city":"Antwerp","zip":"2020","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"facility":"A.Z. Klina","city":"Brasschaat","zip":"2930","country":"Belgium","geoPoint":{"lat":51.2912,"lon":4.49182}},{"facility":"CHU Ambroise Paré","city":"Mons","zip":"7000","country":"Belgium","geoPoint":{"lat":50.45413,"lon":3.95229}},{"facility":"CRIO - Centro Regional Integrado de Oncologia","city":"Fortaleza","state":"Ceará","zip":"60336-045","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"NOB - Núcleo de Oncologia da Bahia","city":"Salvador","state":"Estado de Bahia","zip":"40170-110","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"CEBROM - Centro Brasileiro de Radioterapia, Oncologia e Mastologia","city":"Goiânia","state":"Goiás","zip":"74605-030","country":"Brazil","geoPoint":{"lat":-16.67861,"lon":-49.25389}},{"facility":"Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer","city":"Curitiba","state":"Paraná","zip":"81520-060","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Hospital de Caridade de Ijuí","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Hospital Bruno Born","city":"Lajeado","state":"Rio Grande do Sul","zip":"95900-000","country":"Brazil","geoPoint":{"lat":-29.46694,"lon":-51.96139}},{"facility":"Hospital São Vicente de Paulo","city":"Passo Fundo","state":"Rio Grande do Sul","zip":"99010-080","country":"Brazil","geoPoint":{"lat":-28.26278,"lon":-52.40667}},{"facility":"Hospital de Clínicas de Porto Alegre","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90035-903","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"IMV-Pesquisa Cardiologica Sociedade Simples - HMD - COR","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90470-340","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital São Lucas da PUCRS","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Nossa Senhora da Conceição","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"CEPON - Centro de Pesquisas Oncológicas de Santa Catarina","city":"Florianópolis","state":"Santa Catarina","zip":"88034-000","country":"Brazil","geoPoint":{"lat":-27.59667,"lon":-48.54917}},{"facility":"Clínica de Neoplasias Litoral Ltda.","city":"Itajaí","state":"Santa Catarina","zip":"88301-220","country":"Brazil","geoPoint":{"lat":-26.90778,"lon":-48.66194}},{"facility":"Hospital de Câncer de Barretos - Fundação Pio XII","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Fundação Doutor Amaral Carvalho","city":"Jaú","state":"São Paulo","zip":"17210-120","country":"Brazil","geoPoint":{"lat":-22.29639,"lon":-48.55778}},{"facility":"CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia","city":"Santo André","state":"São Paulo","zip":"09060-650","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"Fundação Faculdade Regional de Medicina de São José do Rio Preto","city":"São José do Rio Preto","state":"São Paulo","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"IBCC - Instituto Brasileiro de Controle do Câncer","city":"São Paulo","state":"São Paulo","zip":"03102-002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"INCA - Instituto Nacional de Câncer","city":"Rio de Janeiro","zip":"20230-230","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Complex Oncological Center - Ruse, EODD","city":"Rousse","zip":"7002","country":"Bulgaria","geoPoint":{"lat":43.84872,"lon":25.9534}},{"facility":"MHAT for women's health - Nadezhda, OOD","city":"Sofia","zip":"1330","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"UMHAT \"Sv. Ivan Rilski\", EAD","city":"Sofia","zip":"1431","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Shato, Ead","city":"Sofia","zip":"1756","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"The Moncton Hospital","city":"Moncton","state":"New Brunswick","zip":"E1C 6Z8","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"Mount Sinai Hospital","city":"Toronto","state":"Ontario","zip":"M5G 1X5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"FALP - Fundación Arturo López Pérez","city":"Santiago","zip":"7500921","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Clinica Santa Maria","city":"Santiago","zip":"7520378","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"IRAM - Instituto de Radio Medicina","city":"Santiago","zip":"7630370","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Hospital Militar de Santiago","city":"Santiago","zip":"7850000","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Hospital Clínico San Borja Arriaran","city":"Santiago","zip":"8360160","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Hospital Clínico Universidad de Chile","city":"Santiago","zip":"8380456","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Hospital Clinico Viña del Mar","city":"Viña del Mar","zip":"2520612","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Centro de Investigaciones Clinicas Viña del Mar","city":"Viña del Mar","zip":"2540364","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Beijing Cancer Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Guangdong General Hospital","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Harbin Medical University Cancer Hospital","city":"Harbin","state":"Heilongjiang","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Liaoning Cancer Hospital & Institute","city":"Shenyang","state":"Liaoning","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Linyi Cancer Hospital","city":"Linyi","state":"Shandong","zip":"276001","country":"China","geoPoint":{"lat":35.06306,"lon":118.34278}},{"facility":"Administradora Country S.A.","city":"Bogotá","zip":"00000","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Fundación Oftalmológica de Santander - FOSCAL","city":"Floridablanca","zip":"6810002","country":"Colombia","geoPoint":{"lat":7.06222,"lon":-73.08644}},{"facility":"Hospital Pablo Tobón Uribe","city":"Medellín","zip":"050034","country":"Colombia","geoPoint":{"lat":6.245,"lon":-75.57151}},{"facility":"IPS IMAT- Instituto Medico de Alta Tecnologia - Oncomedica S.A.","city":"Montería","zip":"230002","country":"Colombia","geoPoint":{"lat":8.75081,"lon":-75.87823}},{"facility":"University Clinic for Pulmonary Diseases","city":"Zagreb","zip":"10 000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"University Hospital Centre \"Sestre Milosrdnice\"","city":"Zagreb","zip":"10000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Bank of Cyprus Oncology Center","city":"Nicosia","zip":"2006","country":"Cyprus","geoPoint":{"lat":35.17284,"lon":33.35397}},{"facility":"Krajska nemocnice Liberec, a.s.","city":"Liberec","zip":"460 63","country":"Czechia","geoPoint":{"lat":50.76711,"lon":15.05619}},{"facility":"Nemocnice Na Plesi s.r.o.","city":"Nová Ves pod Pleší","zip":"26204","country":"Czechia","geoPoint":{"lat":49.83176,"lon":14.27523}},{"facility":"Fakultni nemocnice Olomouc","city":"Olomouc","zip":"775 20","country":"Czechia","geoPoint":{"lat":49.59552,"lon":17.25175}},{"facility":"Vitkovicka nemocnice a.s","city":"Ostrava - Vitkovice","zip":"703 84","country":"Czechia"},{"facility":"Thomayerova nemocnice","city":"Praha 4 - Krc","zip":"140 59","country":"Czechia"},{"facility":"Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.","city":"Ústí nad Labem","zip":"40113","country":"Czechia","geoPoint":{"lat":50.6607,"lon":14.03227}},{"facility":"Herning Sygehus","city":"Herning","zip":"7400","country":"Denmark","geoPoint":{"lat":56.13615,"lon":8.97662}},{"facility":"Roskilde Sygehus","city":"Roskilde","zip":"4000","country":"Denmark","geoPoint":{"lat":55.64152,"lon":12.08035}},{"facility":"North Estonia Medical Centre Foundation","city":"Tallinn","zip":"13419","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"Centre Antoine Lacassagne","city":"Nice","state":"Alpes Maritimes","zip":"06189","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"CHU de Strasbourg - Nouvel Hôpital Civil","city":"Strasbourg","state":"Bas Rhin","zip":"67091","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Hôpital privé Clairval","city":"Marseille","state":"Bouches-du-Rhône","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Hôpital Nord - AP-HM Marseille#","city":"Marseille","state":"Bouches-du-Rhône","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"CHU Besançon - Hôpital Jean Minjoz","city":"Besançon","state":"Doubs","zip":"25030","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"CHU Brest - Hôpital Morvan","city":"Brest","state":"Finistere","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Groupe Hospitalier Sud - Hôpital Haut-Lévêque","city":"Pessac","state":"Gironde","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"CHU Angers - Hôpital Hôtel Dieu#","city":"Angers","state":"Maine Et Loire","zip":"49933","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Hôpital Cochin","city":"Paris","state":"Paris","zip":"75679","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","state":"Pyrenees Atlantiques","zip":"64100","country":"France","geoPoint":{"lat":43.49316,"lon":-1.473}},{"facility":"Centre Hospitalier de la Croix Rousse","city":"Lyon","state":"Rhone","zip":"69317","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Clinique Victor Hugo - Centre Jean Bernard","city":"Le Mans","state":"Sarthe","zip":"72015","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"Institut Sainte Catherine","city":"Avignon","state":"Vaculuse","zip":"84918","country":"France","geoPoint":{"lat":43.94834,"lon":4.80892}},{"facility":"Centre Hospitalier Intercommunal de Créteil","city":"Créteil","state":"Val De Marne","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Hôpital Saint-Louis - Paris","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Universitaetsklinikum Heidelberg","city":"Heidelberg","state":"Baden-Wurttemberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"LungenClinic Grosshansdorf GmbH","city":"Großhansdorf","state":"Schleswig-Holstein","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"251 General Air Force Hospital","city":"Athens","zip":"115 25","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"General Hospital of Athens of Chest Diseases \"SOTIRIA\"","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University General Hospital \"Attikon\"","city":"Athens","zip":"12462","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"General Oncology Hospital of Kifissia \" Agioi Anargyroi\"","city":"Athens","zip":"14564","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Metropolitan General Hospital","city":"Athens","zip":"15562","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University General Hospital of Heraklion","city":"Heraklion","zip":"71110","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"University General Hospital of Patra","city":"Pátrai","zip":"26504","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"Euromedica General Clinic Thessaloniki","city":"Thessaloniki","zip":"54645","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Orszagos Koranyi Pulmonologiai Intezet","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Orszagos Onkologiai Intezet","city":"Budapest","zip":"1122","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Semmelweis Egyetem","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Orszagos Koranyi Pulmonologiai Intezet","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Csongrad Megyei Mellkasi Betegsegek Szakkorhaza","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Petz Aladar Megyei Oktato Korhaz","city":"Győr","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz","city":"Miskolc","zip":"3529","country":"Hungary","geoPoint":{"lat":48.10327,"lon":20.77806}},{"facility":"SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz","city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Tolna Megyei Balassa Janos Korhaz","city":"Szekszárd","zip":"7100","country":"Hungary","geoPoint":{"lat":46.34723,"lon":18.71189}},{"facility":"Tudogyogyintezet Torokbalint","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Zala Megyei Szent Rafael Korhaz","city":"Zalaegerszeg","zip":"8900","country":"Hungary","geoPoint":{"lat":46.83695,"lon":16.84401}},{"facility":"Cork University Hospital","city":"Cork","country":"Ireland","geoPoint":{"lat":51.89797,"lon":-8.47061}},{"facility":"Soroka University Medical Center","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Rambam Health Care Center","city":"Haifa","zip":"3109601","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Hadassah University Hospital - Ein Kerem","city":"Jerusalem","zip":"9112001","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Sapir Medical Center, Meir Hospital","city":"Kfar Saba","zip":"4428164","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Rabin Medical Center-Beilinson Campus","city":"Petah Tikva","zip":"49100","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Chaim Sheba Medical Center","city":"Ramat Gan","zip":"5265601","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Kaplan Medical Center","city":"Rehovot","zip":"7610001","country":"Israel","geoPoint":{"lat":31.89421,"lon":34.81199}},{"facility":"Assaf Harofeh","city":"Rishon LeZiyyon","zip":"75141","country":"Israel","geoPoint":{"lat":31.97102,"lon":34.78939}},{"facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","zip":"6423906","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Ospedale Mater Salutis","city":"Legnago","state":"Verona","zip":"37045","country":"Italy","geoPoint":{"lat":45.19365,"lon":11.30227}},{"facility":"Fondazione Poliambulanza Istituto Ospedaliero","city":"Brescia","zip":"25124","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"Presidio Ospedaliero Garibaldi Nesima","city":"Catania","zip":"95100","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Azienda Ospedaliero Universitaria San Martino","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Seconda Università degli Studi di Napoli","city":"Napoli","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Azienda Ospedaliero Universitaria di Parma","city":"Parma","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Azienda Ospedaliero Universitaria Pisana","city":"Pisa","zip":"56126","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"National Cancer Center Hospital East","city":"Kashiwa-shi","state":"Chiba","zip":"277-8577","country":"Japan"},{"facility":"Kurume University Hospital","city":"Kurume-shi","state":"Fukuoka","zip":"830-0011","country":"Japan"},{"facility":"NHO Hokkaido Cancer Center","city":"Sapporo","state":"Hokkaido","zip":"003-0804","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Institute of Biomedical Research and Innovation Hospital","city":"Kobe","state":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Kobe City Hospital Organization Kobe City Medical Center General Hospital","city":"Kobe","state":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Yokohama Municipal Citizen's Hospital","city":"Yokohama","state":"Kanagawa","zip":"240-8555","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kanagawa Cancer Center","city":"Yokohama","state":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kansai Medical University Hospital","city":"Hirakata-shi","state":"Osaka","zip":"573-1191","country":"Japan"},{"facility":"Osaka Medical College Hospital","city":"Takatsuki-shi","state":"Osaka","zip":"569-8686","country":"Japan"},{"facility":"National Cancer Center Hospital","city":"Chūōku","state":"Tokyo-To","zip":"104-0045","country":"Japan","geoPoint":{"lat":33.63867,"lon":130.67068}},{"facility":"Tokyo Medical University Hospital","city":"Shinjuku-ku","state":"Tokyo-To","zip":"160-0023","country":"Japan"},{"facility":"Toyama University Hospital","city":"Toyama","state":"Toyama","zip":"930-0194","country":"Japan","geoPoint":{"lat":36.7,"lon":137.21667}},{"facility":"Kobe City Hospital Organization Kobe City Medical Center General Hospital","city":"Kobe","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"American University of Beirut Medical Center","city":"Beirut","zip":"1107 2020","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Rafik Hariri University Hospital","city":"Beirut","zip":"113-6044","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Hotel Dieu de France Hospital","city":"Beirut","zip":"166830","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Mount Lebanon Hospital","city":"Beirut","zip":"470","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Hammoud Hospital University Medical Center","city":"Saida","zip":"652","country":"Lebanon","geoPoint":{"lat":33.55751,"lon":35.37148}},{"facility":"Hospital of Lithuanian University of Health Sciences Kaunas Clinics","city":"Kaunas","zip":"50009","country":"Lithuania","geoPoint":{"lat":54.90156,"lon":23.90909}},{"facility":"Martini Ziekenhuis","city":"Groningen","zip":"9728 NT","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Westfriesgasthuis - PARENT","city":"Hoorn","zip":"1624 NP","country":"Netherlands","geoPoint":{"lat":52.6425,"lon":5.05972}},{"facility":"ETZ Elisabeth","city":"Tilburg","zip":"5022 GC","country":"Netherlands","geoPoint":{"lat":51.55551,"lon":5.0913}},{"facility":"Auckland City Hospital","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Dunedin Public Hospital","city":"Dunedin","zip":"9016","country":"New Zealand","geoPoint":{"lat":-45.87416,"lon":170.50361}},{"facility":"Waikato Hospital","city":"Hamilton","zip":"3200","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Palmerston North Hospital","city":"Palmerston North","zip":"4414","country":"New Zealand","geoPoint":{"lat":-40.35636,"lon":175.61113}},{"facility":"Tauranga Hospital","city":"Tauranga","zip":"3143","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Wellington Hospital","city":"Wellington","zip":"6021","country":"New Zealand","geoPoint":{"lat":-41.28664,"lon":174.77557}},{"facility":"Instituto Nacional de Enfermedades Neoplásicas","city":"Lima","zip":"LIMA 34","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Clinica Internacional Sede San Borja","city":"Lima","zip":"LIMA 41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Oncosalud","city":"Lima","zip":"Lima 41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Instytut MSF Sp. o.o","city":"Lodz","zip":"90-302","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi","city":"Lodz","zip":"93-513","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"KO-MED Centra Kliniczne Lublin II","city":"Lublin","zip":"20-362","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"SSZZOZ im. Dr Teodora Dunina w Rudce","city":"Mrozy","zip":"05-320","country":"Poland","geoPoint":{"lat":52.16609,"lon":21.80263}},{"facility":"SP Zespol Gruzlicy i Chorob Pluc w Olsztynie","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Izerskie Centrum Pulmonologii i Chemioterapii \"IZER-MED\" Spolka z o.o.","city":"Szklarska Poręba","zip":"58-580","country":"Poland","geoPoint":{"lat":50.82567,"lon":15.52274}},{"facility":"Centrum Onkologii-Instytut im. M. Sklodowskiej Curie","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Mazowiecki Szpital Onkologiczny","city":"Wieliszew","zip":"05-135","country":"Poland","geoPoint":{"lat":52.4513,"lon":20.96827}},{"facility":"Hospital Garcia de Orta, EPE","city":"Almada","zip":"2801-915","country":"Portugal","geoPoint":{"lat":38.67902,"lon":-9.1569}},{"facility":"Hospital Professor Doutor Fernando Fonseca, E.P.E.","city":"Amadora-Lisbon","zip":"2610-276","country":"Portugal"},{"facility":"Centro Hospitalar De Coimbra-CHUC","city":"Coimbra","zip":"3041-801","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Centro Hospitalar e Universitário de Coimbra, E.P.E (CHC)","city":"Coimbra","zip":"3041-801","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital Pulido Valente","city":"Lisbon","zip":"1769-001","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos","city":"Lisbon","zip":"1849-017","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António","city":"Porto","zip":"4099-001","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Hospital CUF Porto","city":"Porto","zip":"4100-180","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Instituto Português de Oncologia do Porto Francisco Gentil, EPE","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Centro Hospitalar de São João, E.P.E.","city":"Porto","zip":"4200-319","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião","city":"Santa Maria da Feira","zip":"4520-211","country":"Portugal","geoPoint":{"lat":40.92726,"lon":-8.54839}},{"facility":"Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E","city":"Vila Nova de Gaia","zip":"4434-502","country":"Portugal","geoPoint":{"lat":41.12401,"lon":-8.61241}},{"facility":"Spitalul Judetean de Urgenta \"Dr. Constantin Opris\" Baia Mare","city":"Baia Mare","zip":"430031","country":"Romania","geoPoint":{"lat":47.65729,"lon":23.56808}},{"facility":"S.C Policlinica de Diagnostic Rapid S.A","city":"Brasov","zip":"500152","country":"Romania","geoPoint":{"lat":45.64861,"lon":25.60613}},{"facility":"Institutul Oncologic \"Prof. Dr. Al. Trestioreanu\"","city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Spitalul Clinic Coltea","city":"Bucharest","zip":"030171","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"S.C Gral Medical S.R.L","city":"Bucharest","zip":"031422","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Institutul Oncologic \"Prof. Dr. Ion Chiricuta\" Cluj Napoca","city":"Cluj-Napoca","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"S.C Medisprof S.R.L","city":"Cluj-Napoca","zip":"400058","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Spitalul Militar de Urgenta \"Dr.Constantin Papilian\"Cluj -Napoca","city":"Cluj-Napoca","zip":"400132","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"S.C Radiotherapy Center Cluj S.R.L","city":"Comuna Floresti","zip":"407280","country":"Romania"},{"facility":"Spitalul Clinic Judetean de Urgenta \"Sf. Apostol Andrei\" Constanta","city":"Constanța","zip":"900591","country":"Romania","geoPoint":{"lat":44.18073,"lon":28.63432}},{"facility":"S.C Centrul de Oncologie Sf. Nectarie S.R.L","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Institutul Regional de Oncologie Iasi","city":"Iași","zip":"700483","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"S.C Pelican Impex S.R.L","city":"Oradea","zip":"410469","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"Spitalul Clinic Municipal \"Dr. Gavril Curteanu\" Oradea","city":"Oradea","zip":"410469","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"Spitalul Judetean de Urgenta \"Sf. Ioan cel Nou\" Suceava","city":"Suceava","zip":"720201","country":"Romania","geoPoint":{"lat":47.63333,"lon":26.25}},{"facility":"S.C Oncocenter Oncologie Clinica S.R.L","city":"Timișoara","zip":"300210","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"S.C Oncomed S.R.L","city":"Timișoara","zip":"300239","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"SBIH of Arkhangelsk region \"Arkhangelsk Clinical Oncological Dispensary\"","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"LLC Evimed","city":"Chelyabinsk","zip":"454048","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Chelyabinsk Regional Oncology Dispensary","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Irkutsk Regional Oncology Dispensary","city":"Irkutsk","zip":"664035","country":"Russia","geoPoint":{"lat":52.29566,"lon":104.29076}},{"facility":"RBIH \"Ivanovo Regional Oncological Dispensary\"","city":"Ivanovo","zip":"153040","country":"Russia","geoPoint":{"lat":56.99988,"lon":40.97257}},{"facility":"SBHI of Kaluga Region \"Kaluga regional clinical oncology dispensary\"","city":"Kaluga","zip":"248007","country":"Russia","geoPoint":{"lat":54.53063,"lon":36.27}},{"facility":"SAIH \"Republican Clinical Oncological Dispensary of the Ministry of Healthcare of Republic Tatarstan","city":"Kazan'","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Kemerovo SPI Regional Clinical Oncology Dispensary","city":"Kemerovo","zip":"650036","country":"Russia","geoPoint":{"lat":55.35417,"lon":86.10435}},{"facility":"SBHI \"Krasnoyarsk Regional Oncology Dispensary n.a. A.I. Kryzhanovsky\"","city":"Krasnoyarsk","zip":"660133","country":"Russia","geoPoint":{"lat":56.03742,"lon":92.93136}},{"facility":"RBIH \"Kursk regional clinical oncology dispensary\" of Kursk Region Healthcare Committee","city":"Kursk","zip":"305035","country":"Russia","geoPoint":{"lat":51.72689,"lon":36.18457}},{"facility":"FSBSI \"Russian Oncological Scientific Center n.a. N.N. Blokhin\"","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Murmansk Regional Clinical Hospital named after Bayandin","city":"Murmansk","zip":"183047","country":"Russia","geoPoint":{"lat":68.96778,"lon":33.09922}},{"facility":"SBHI of Novosibirsk region \"Novosibirsk Regional Oncological Dispensary\"","city":"Novosibirsk","zip":"630108","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"SBIH of Stavropol territory \"Pyatigorsk Oncological Dispensary\"","city":"Pyatigorsk","zip":"357502","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"FSBHI Clinical research institute of phthisiopulmonology","city":"Saint Petersburg","zip":"191036","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"SBIH \"Leningrad Regional Oncological Dispensary\"","city":"Saint Petersburg","zip":"191104","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"\"Bio Eq\" LLC","city":"Saint Petersburg","zip":"197342","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"FBI \"Scientific Research Institute of Oncology n. a. N. N. Petrov\"","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"SBIH \"Samara Regional Clinical Oncological Dispensary\"","city":"Samara","zip":"443031","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"SBIH \"Oncological Dispensary # 2\" of the MoH of Krasnodar territory","city":"Sochi","zip":"354057","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"Tomsk Research Instutite of Oncology","city":"Tomsk","zip":"634028","country":"Russia","geoPoint":{"lat":56.50049,"lon":84.98216}},{"facility":"BHI of Omsk region \"Clinical Oncology Dispensary\"","city":"Tomsk","zip":"644013","country":"Russia","geoPoint":{"lat":56.50049,"lon":84.98216}},{"facility":"Medicinskiy gorod","city":"Tyumen","zip":"625041","country":"Russia","geoPoint":{"lat":57.15222,"lon":65.52722}},{"facility":"SBIH of Yaroslavl region \"Regional Clinical Oncological Hospital\"","city":"Yaroslavl","zip":"150054","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"Clinical Center of Serbia","city":"Belgrade","zip":"11 000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Institute of Oncology and Radiology of Serbia","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Military Medical Academy","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Center Bezanijska Kosa","city":"Belgrade","zip":"11080","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Center Nis, Pulmonary Diseases Clinic","city":"Gornji Matejevac","zip":"18204","country":"Serbia","geoPoint":{"lat":43.36472,"lon":21.96793}},{"facility":"Institute for Pulmonary Diseases of Vojvodina","city":"Kamenitz","zip":"21204","country":"Serbia","geoPoint":{"lat":45.22334,"lon":19.84263}},{"facility":"Clinical Center Kragujevac","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"National University Cancer Institute","city":"Singapore","zip":"119074","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Centre","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Tan Tock Seng Hospital","city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Nemocnica s poliklinikou Sv. Jakuba, n.o. Bardejov","city":"Bardejov","zip":"08501","country":"Slovakia","geoPoint":{"lat":49.29175,"lon":21.27271}},{"facility":"Univerzitna nemocnica Bratislava, Nemocnica Ruzinov","city":"Bratislava","zip":"82606","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Emery Clinical Services","city":"Alberton","state":"Gauteng","zip":"1449","country":"South Africa","geoPoint":{"lat":-26.26786,"lon":28.12225}},{"facility":"University of Pretoria Oncology Department","city":"Pretoria","state":"Gauteng","zip":"0002","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Johese Clinical Research","city":"Pretoria","state":"Gauteng","zip":"1692","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Cape Town Oncology Trials Pty Ltd","city":"Cape Town","state":"Western Cape","zip":"7570","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Yonsei University Wonju Severance Christian Hospital","city":"Wŏnju","state":"Gangwon-do","zip":"26426","country":"South Korea","geoPoint":{"lat":37.35139,"lon":127.94528}},{"facility":"Inje University Haeundae Paik Hospital","city":"Busan","state":"Gyeonggi-do","zip":"48108","country":"South Korea"},{"facility":"National Cancer Center","city":"Goyang-si","state":"Gyeonggi-do","zip":"10408","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"CHA Bundang Medical Center, CHA University","city":"Seongnam-si","state":"Gyeonggi-do","zip":"13496","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","state":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"The Catholic University of Korea, St. Vincent's Hospital","city":"Suwon","state":"Gyeonggi-do","zip":"16247","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Ajou University Hospital","city":"Suwon","state":"Gyeonggi-do","zip":"443-380","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Chungbuk National University Hospital","city":"Cheongju-si","state":"North Chungcheong","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Kyungpook National University Chilgok Hospital","city":"Daegu","zip":"41404","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Gachon University Gil Medical Center","city":"Incheon","zip":"21565","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Korea University Anam Hospital","city":"Seoul","zip":"02841","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea, Seoul St. Mary's Hospital","city":"Seoul","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea, Yeouido St. Mary's Hospital","city":"Seoul","zip":"07345","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","city":"Seoul","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan University Hospital","city":"Ulsan","zip":"44033","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"Hospital de Mataro","city":"Mataró","state":"Barcelona","zip":"08304","country":"Spain","geoPoint":{"lat":41.54211,"lon":2.4445}},{"facility":"Hospital Universitario Mutua de Terrassa","city":"Terrassa","state":"Barcelona","zip":"08221","country":"Spain","geoPoint":{"lat":41.56667,"lon":2.01667}},{"facility":"Hospital Universitario Donostia","city":"Donostia / San Sebastian","state":"Guipuzcoa","zip":"20014","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Complejo Hospitalario Universitario de Santiago","city":"Santiago de Compostela","state":"La Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Complejo Hospitalario Universitario de Vigo","city":"Vigo","state":"Pontevedra","zip":"36204","country":"Spain","geoPoint":{"lat":42.23282,"lon":-8.72264}},{"facility":"Specialist","city":"Barcelona","zip":"08006","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Quiron Dexeus","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"ICO Girona - Hospital Universitari de Girona Dr. Josep Trueta","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Hospital General Universitario Gregorio Marañon","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"MD Anderson Cancer Centre","city":"Madrid","zip":"28033","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Fundacion Jimenez Diaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario de Malaga","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Quiron Sagrado Corazon","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Txagorritxu","city":"Vitoria-Gasteiz","zip":"01009","country":"Spain","geoPoint":{"lat":42.84998,"lon":-2.67268}},{"facility":"Kaohsiung Chang Gung Memorial Hospital","city":"Kaohsiung City","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Tri-Service General Hospital","city":"Taipei","zip":"11490","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Chang Gung Memorial Hospital, Linkou","city":"Taoyuan","zip":"333","country":"Taiwan","geoPoint":{"lat":24.99368,"lon":121.29696}},{"facility":"King Chulalongkorn Memorial Hospital","city":"Patumwan","state":"Bangkok","zip":"10330","country":"Thailand"},{"facility":"Rajavithi Hospital","city":"Rajathevee","state":"Bangkok","zip":"10400","country":"Thailand"},{"facility":"Srinagarind Hospital","city":"Muang","state":"Changwat Khon Kaen","zip":"40002","country":"Thailand"},{"facility":"Naresuan University Hospital","city":"Muang","state":"Changwat Phitsanulok","zip":"65000","country":"Thailand"},{"facility":"Songklanagarind Hospital","city":"Hat Yai","state":"Changwat Songkhla","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Maharaj Nakorn Chiang Mai Hospital","city":"Muang","state":"Chiang Mai","zip":"50200","country":"Thailand"},{"facility":"Siriraj Hospital","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Acibadem Adana Hospital","city":"Adana","zip":"01130","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Baskent University Adana Application and Research Center","city":"Adana","zip":"01220","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Adana Numune Training and Research Hospital","city":"Adana","zip":"01240","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Cukurova University Medical Faculty","city":"Adana","zip":"01330","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Adana City Hospital","city":"Adana","zip":"01370","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Ankara University Medical Faculty","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Hacettepe University Medical Faculty","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Memorial Antalya Hastanesi","city":"Antalya","zip":"07020","country":"Turkey (Türkiye)","geoPoint":{"lat":36.90812,"lon":30.69556}},{"facility":"Okmeydani Research and Training Hospital","city":"Istanbul","zip":"34000","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Istanbul University Cerrahpasa Medical Faculty","city":"Istanbul","zip":"34098","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital","city":"Istanbul","zip":"34147","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Medipol University Medical Faculty","city":"Istanbul","zip":"34214","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Kartal Lutfi Kirdar Research and Training Hospital","city":"Istanbul","zip":"34890","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege University Medical Faculty","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Inonu Uni. Med. Fac.","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Mersin University Medical Faculty","city":"Mersin","zip":"33169","country":"Turkey (Türkiye)","geoPoint":{"lat":36.81196,"lon":34.63886}},{"facility":"Sakarya Traning and Research Hospital","city":"Sakarya","zip":"54187","country":"Turkey (Türkiye)","geoPoint":{"lat":39.50333,"lon":32.07583}},{"facility":"Namik Kemal University","city":"Tekirdağ","zip":"59100","country":"Turkey (Türkiye)","geoPoint":{"lat":40.9781,"lon":27.51101}},{"facility":"CI Chernivtsi RC Oncological Dispensary Bukovinian SMU Ch of Oncology and Radiology","city":"Chernivtsi","zip":"58013","country":"Ukraine","geoPoint":{"lat":48.29045,"lon":25.93241}},{"facility":"CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU","city":"Dnipro","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU","city":"Ivano-Frankivsk","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"SI S.P.Grygoriev Institute of Medical Radiology of NAMSU","city":"Kharkiv","zip":"61024","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Communal Non-profit Enterprise Regional Center of Oncology","city":"Kharkiv","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Kherson Regional Oncologic Dispensary","city":"Kherson","zip":"73000","country":"Ukraine","geoPoint":{"lat":46.63695,"lon":32.61458}},{"facility":"Treatment-Diagnostic Center of Private Enterprise of PPC Atsynus","city":"Kropyvnytskyi","zip":"25006","country":"Ukraine","geoPoint":{"lat":48.50834,"lon":32.26618}},{"facility":"CI Kryvyi Rih Oncological Dispensary of DRC","city":"Kryvyi Rih, Dnipropetrovsk Region","zip":"50048","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"Kyiv City Clinical Oncological Center","city":"Kyiv","zip":"03115","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Treatment-Prevention Institution Volyn Regional Oncological Dispensary","city":"Lutsk","zip":"43018","country":"Ukraine","geoPoint":{"lat":50.75784,"lon":25.35024}},{"facility":"Lviv State Oncological Regional Treatment and Diagnostic Center","city":"Lviv","zip":"79031","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Odesa Regional Oncologic Dispensary","city":"Odesa","zip":"65055","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"RCI Sumy Regional Clinical Oncological Dispensary","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"CCCH City Oncological Center SHEI Uzhgorod NU","city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Podilskyi Regional Oncological Center","city":"Vinnytsia","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Vinnytsia Regional Clinical Oncological Dispensary","city":"Vinnytsia","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Southend University Hospital","city":"Westcliff-on-Sea","state":"Essex","zip":"SS0 0RY","country":"United Kingdom","geoPoint":{"lat":51.54424,"lon":0.69179}},{"facility":"Cheltenham General Hospital","city":"Cheltenham","state":"Gloucestershire","zip":"GL53 7AN","country":"United Kingdom","geoPoint":{"lat":51.90006,"lon":-2.07972}},{"facility":"Chelsea and Westminster Hospital","city":"London","state":"Greater London","zip":"SW109NH","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Mount Vernon Hospital","city":"Stevenage","state":"Hertfordshire","zip":"SG1 4AB","country":"United Kingdom","geoPoint":{"lat":51.90224,"lon":-0.20256}},{"facility":"The Clatterbridge Cancer Centre","city":"Metropolitan Borough of Wirral","state":"Merseyside","zip":"CH63 4JY","country":"United Kingdom","geoPoint":{"lat":53.37616,"lon":-3.10501}},{"facility":"Royal Stoke University Hospital","city":"Stoke-on-Trent","state":"Staffordshire","zip":"ST4 6QG","country":"United Kingdom","geoPoint":{"lat":53.00415,"lon":-2.18538}}]},"referencesModule":{"references":[{"pmid":"37748693","type":"RESULT","citation":"Reck M, Barlesi F, Yang JC, Westeel V, Felip E, Ozguroglu M, Dols MC, Sullivan R, Kowalski DM, Andric Z, Lee DH, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Mehr KT, Park K. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial. J Thorac Oncol. 2024 Feb;19(2):297-313. doi: 10.1016/j.jtho.2023.09.1445. Epub 2023 Sep 24."}],"seeAlsoLinks":[{"label":"Trial Awareness and Transparency website","url":"https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR%20100070-005"},{"label":"US Medical Information website, Medical Resources","url":"https://medical.emdserono.com/en_US/home.html"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"FG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"FG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"366"},{"groupId":"FG001","numSubjects":"322"},{"groupId":"FG002","numSubjects":"526"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"366"},{"groupId":"FG001","numSubjects":"322"},{"groupId":"FG002","numSubjects":"526"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"BG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"BG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"366"},{"groupId":"BG001","value":"322"},{"groupId":"BG002","value":"526"},{"groupId":"BG003","value":"1214"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"289"},{"groupId":"BG003","value":"647"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"237"},{"groupId":"BG003","value":"567"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"145"},{"groupId":"BG003","value":"298"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"282"},{"groupId":"BG001","value":"253"},{"groupId":"BG002","value":"381"},{"groupId":"BG003","value":"916"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"72"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"338"},{"groupId":"BG001","value":"296"},{"groupId":"BG002","value":"466"},{"groupId":"BG003","value":"1100"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"42"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"104"},{"groupId":"BG003","value":"242"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"250"},{"groupId":"BG002","value":"375"},{"groupId":"BG003","value":"879"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"85"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"High PD-L1+ FAS included all high expression PD-L1+ participants who were randomized to study intervention. High expression PD-L1+ participants with greater than or equal to (\\>=) 80 percent (%) of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"216"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"5.4","upperLimit":"12.6"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.4","upperLimit":"6.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0070","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"0.93"}]},{"type":"PRIMARY","title":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly Avelumab was included into the randomization allocation. The PDL1+ participants with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"4.2","upperLimit":"11.1"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.0","upperLimit":"6.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0196","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"0.98"}]},{"type":"PRIMARY","title":"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"High PD-L1+ FAS included all high expression PD-L1+ participants who were randomized to study intervention. High expression PD-L1+ participants with greater than or equal to (\\>=) 80 percent (%) of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"216"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","lowerLimit":"15.0","upperLimit":"24.3"},{"groupId":"OG001","value":"14.9","lowerLimit":"11.8","upperLimit":"18.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1032","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.67","ciUpperLimit":"1.09"}]},{"type":"PRIMARY","title":"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly Avelumab was included into the randomization allocation. The PDL1+ participants with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","lowerLimit":"14.0","upperLimit":"28.1"},{"groupId":"OG001","value":"15.3","lowerLimit":"11.6","upperLimit":"19.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0630","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.79","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"1.07"}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"Moderate and High PD-L1+ FAS included all high expression PDL-L1+ participants who were randomized to study intervention. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"304"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"5.4","upperLimit":"9.6"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.5","upperLimit":"6.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0147","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"0.98"}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"Moderate and High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly avelumab was included into the randomization allocation. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"2.8","upperLimit":"8.2"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.5","upperLimit":"6.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1753","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.67","ciUpperLimit":"1.15"}]},{"type":"SECONDARY","title":"Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"Moderate and High PD-L1+ FAS included all high expression PD-L1+ participants who were randomized to study intervention. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"304"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","lowerLimit":"14.6","upperLimit":"21.7"},{"groupId":"OG001","value":"13.3","lowerLimit":"11.4","upperLimit":"16.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0257","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"1.00"}]},{"type":"SECONDARY","title":"Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"Moderate and High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly avelumab was included into the randomization allocation. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"12.5","upperLimit":"21.3"},{"groupId":"OG001","value":"13.0","lowerLimit":"11.1","upperLimit":"17.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0809","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"1.07"}]},{"type":"SECONDARY","title":"Overall Survival (OS) in Full Analysis Set (FAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"FAS included all participants who were randomized to study intervention.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"526"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"12.5","upperLimit":"19.1"},{"groupId":"OG001","value":"14.3","lowerLimit":"11.8","upperLimit":"15.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1294","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"1.07"}]},{"type":"SECONDARY","title":"Overall Survival (OS) in Modified Full Analysis Set (mFAS)","description":"OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.","populationDescription":"mFAS included all participants who were randomized to study intervention after weekly avelumab was included into the randomization allocation.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"321"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"12.1","upperLimit":"18.1"},{"groupId":"OG001","value":"14.8","lowerLimit":"11.6","upperLimit":"16.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2618","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.13"}]},{"type":"SECONDARY","title":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","populationDescription":"High PD-L1+ FAS included all high expression PD-L1+ participants who were randomized to study intervention. High expression PD-L1+ participants with greater than or equal to (\\>=) 80 percent (%) of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"216"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","lowerLimit":"30.0","upperLimit":"46.0"},{"groupId":"OG001","value":"30.1","lowerLimit":"24.1","upperLimit":"36.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0640","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.91","ciUpperLimit":"2.18"}]},{"type":"SECONDARY","title":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","populationDescription":"High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly Avelumab was included into the randomization allocation. The PDL1+ participants with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","lowerLimit":"26.5","upperLimit":"43.5"},{"groupId":"OG001","value":"30.2","lowerLimit":"22.5","upperLimit":"38.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2217","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"2.07"}]},{"type":"SECONDARY","title":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","populationDescription":"Moderate and High PD-L1+ FAS included all high expression PD-L1+ participants who were randomized to study intervention. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"304"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","lowerLimit":"27.3","upperLimit":"40.2"},{"groupId":"OG001","value":"30.3","lowerLimit":"25.1","upperLimit":"35.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1912","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.81","ciUpperLimit":"1.72"}]},{"type":"SECONDARY","title":"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set","description":"Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","populationDescription":"Moderate and High PD-L1+ mFAS included all high expression PD-L1+ participants who were randomized to study intervention after weekly avelumab was included into the randomization allocation. The PD-L1+ participants with \\>= 50% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"24.0","upperLimit":"37.8"},{"groupId":"OG001","value":"30.6","lowerLimit":"24.0","upperLimit":"37.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4951","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"1.57"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)","description":"DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"High PD-L1+ FAS was used. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","lowerLimit":"1.4","upperLimit":"60.8"},{"groupId":"OG001","value":"8.4","lowerLimit":"1.0","upperLimit":"63.9"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)","description":"DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"High PD-L1+ mFAS was used. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","lowerLimit":"3.8","upperLimit":"43.9"},{"groupId":"OG001","value":"8.4","lowerLimit":"1.0","upperLimit":"35.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment","description":"EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.","populationDescription":"High PD-L1+HRQoL analysis set includes all high expression PD-L1+ FAS participants who have 1 baseline HRQoL assessment and have \\>=1 post-baseline HRQoL questionnaire complete. The high expression PDL1+ participants were with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeter (mm)","timeFrame":"Baseline, End of treatment (up to Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"23.61"},{"groupId":"OG001","value":"-5.2","spread":"20.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.","populationDescription":"High PD-L1+ Modified HRQoL Analysis Set included all mFAS participants who have 1 baseline HRQoL assessment and have \\>=1 post-baseline HRQoL questionnaire completed. The high expression PDL1+ participants were with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeter","timeFrame":"Baseline, End of treatment (Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"22.49"},{"groupId":"OG001","value":"-3.9","spread":"20.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","populationDescription":"High PD-L1+HRQoL analysis set includes all high expression PD-L1 FAS participants who have 1 baseline HRQoL assessment and have \\>=1 post-baseline HRQoL questionnaire complete. The high expression PDL1+ participants were with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, End of treatment (up to Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"22.30"},{"groupId":"OG001","value":"-6.1","spread":"24.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","populationDescription":"High PD-L1+modified HRQoL analysis set includes all high expression PD-l1+ mFAS participants who have 1 baseline HRQoL assessment and have ≥1 post-baseline HRQoL questionnaire completed. The high expression PDL1+ participants were with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, End of treatment (Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.9","spread":"21.03"},{"groupId":"OG001","value":"-4.5","spread":"23.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set","description":"EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).","populationDescription":"High PD-L1+ HRQoL analysis set includes all high expression PD-L1+ FAS participants who have 1 baseline HRQoL assessment and have \\>=1 post-baseline HRQoL questionnaire complete. The high expression PDL1+ participants were with \\>= 80% of tumor cells deemed positive for PD-L1 expression at any staining intensity (1+, 2+, or 3+). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, End of treatment (up to Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"108"}]}],"classes":[{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"24.10"},{"groupId":"OG001","value":"5.2","spread":"19.66"}]}]},{"title":"Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"29.04"},{"groupId":"OG001","value":"-4.3","spread":"27.01"}]}]},{"title":"Hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"21.48"},{"groupId":"OG001","value":"1.5","spread":"13.95"}]}]},{"title":"Sore mouth","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"18.28"},{"groupId":"OG001","value":"1.9","spread":"21.77"}]}]},{"title":"Dysphagia","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"19.36"},{"groupId":"OG001","value":"-0.6","spread":"21.36"}]}]},{"title":"Peripheral neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"17.60"},{"groupId":"OG001","value":"10.8","spread":"24.46"}]}]},{"title":"Alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"8.98"},{"groupId":"OG001","value":"14.2","spread":"32.93"}]}]},{"title":"Pain in chest","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"22.96"},{"groupId":"OG001","value":"-1.5","spread":"26.33"}]}]},{"title":"Pain in arm or shoulder","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"32.71"},{"groupId":"OG001","value":"1.9","spread":"26.50"}]}]},{"title":"Pain in other parts","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"33.29"},{"groupId":"OG001","value":"1.5","spread":"30.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set","description":"EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).","populationDescription":"High PD-L1+ modified HRQoL analysis set was used. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"number analyzed\" signifies those participants who were evaluable for specified categories.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, End of treatment (up to Week 283.9)","groups":[{"id":"OG000","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"classes":[{"title":"Dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"27.19"},{"groupId":"OG001","value":"4.9","spread":"18.77"}]}]},{"title":"Coughing","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"28.87"},{"groupId":"OG001","value":"-5.2","spread":"24.34"}]}]},{"title":"Hemoptysis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"17.89"},{"groupId":"OG001","value":"0.0","spread":"12.59"}]}]},{"title":"Sore mouth","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"13.97"},{"groupId":"OG001","value":"1.9","spread":"17.71"}]}]},{"title":"Dysphagia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"14.10"},{"groupId":"OG001","value":"-0.5","spread":"22.88"}]}]},{"title":"Peripheral neuropathy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"21.17"},{"groupId":"OG001","value":"9.9","spread":"23.49"}]}]},{"title":"Alopecia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"17.11"},{"groupId":"OG001","value":"15.0","spread":"29.70"}]}]},{"title":"Pain in chest","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"29.13"},{"groupId":"OG001","value":"-0.5","spread":"25.50"}]}]},{"title":"Pain in arm or shoulder","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"30.69"},{"groupId":"OG001","value":"1.4","spread":"25.46"}]}]},{"title":"Pain in other parts","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"28.93"},{"groupId":"OG001","value":"1.4","spread":"28.97"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs)","description":"Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAEs were those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period TEAEs included both serious TEAEs and non-serious TEAEs. Any AE that was suspicious to be a potential Immune-related adverse event (irAE) including infusion related reactions were considered AESIs. Number of participants with TEAEs and AESIs were reported.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"308"},{"groupId":"OG002","value":"484"}]}]},{"title":"AESIs","categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"173"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03","description":"Number of participants with shifts from Baseline values (Grade 0/1/2/3) to abnormal post-baseline values (shift to \\>= Grade 4) were reported as per NCI-CTCAE, v4.03 graded from Grade 1 to 5. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death. Shifts in laboratory parameter (anemia, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, white blood cell count decreased, alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased and Hyperglycemia) were reported.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Anemia: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"58"}]}]},{"title":"Anemia: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"30"}]}]},{"title":"Anemia: Grade 2 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"Lymphocyte count decreased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"31"}]}]},{"title":"Lymphocyte count decreased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]},{"title":"Lymphocyte count decreased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}]}]},{"title":"Lymphocyte count decreased: Grade 2 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"12"}]}]},{"title":"Lymphocyte count decreased: Grade 2 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Lymphocyte count decreased: Grade 3 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Neutrophil count decreased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"65"}]}]},{"title":"Neutrophil count decreased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"25"}]}]},{"title":"Neutrophil count decreased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Platelet count decreased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"18"}]}]},{"title":"Platelet count decreased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"}]}]},{"title":"Platelet count decreased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"White blood cell count decreased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"24"}]}]},{"title":"White blood cell count decreased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"}]}]},{"title":"Alanine aminotransferase increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}]}]},{"title":"Alanine aminotransferase increased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"Alanine aminotransferase increased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Alkaline phosphatase increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Alkaline phosphatase increased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Alkaline phosphatase increased: Grade 1 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Alkaline phosphatase increased: Grade 2 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Aspartate aminotransferase increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"Aspartate aminotransferase increased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Aspartate aminotransferase increased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Blood bilirubin increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"Blood bilirubin increased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Creatine phosphokinase increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"Creatine phosphokinase increased: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Creatine phosphokinase increased: Grade 1 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Creatine phosphokinase increased: Grade 2 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Creatinine increased: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}]},{"title":"Creatinine increased: Grade 1 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Hyperglycemia: Grade 0 to Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"35"}]}]},{"title":"Hyperglycemia: Grade 0 to Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase","description":"The number of participants with changes from baseline in increased Body Temperature (degree Celsius \\[°C\\]) were reported by using criteria: Baseline temperature (temp.) less than (\\<) 37°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, greater than or equal to (\\>=)3°C and missing; Baseline temp. 37 - \\<38°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. 38 - \\<39°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. 39-\\<40°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. \\>=40°C, on treatment change \\<1°C, 1 - \\<2°C, 2 - \\<3°C, \\>=3°C and missing; Baseline temp. missing, on treatment change missing.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Baseline temp. <37°C, on treatment change <1°C","categories":[{"measurements":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"256"},{"groupId":"OG002","value":"403"}]}]},{"title":"Baseline temp.<37°C, on treatment change 1 - <2°C","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}]}]},{"title":"Baseline temp. <37°C, on treatment change 2 - <3°C","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. <37°C, on treatment change >=3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. <37°C, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"}]}]},{"title":"Baseline temp. 37 - <38°C, on treatment change <1°C","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"37"}]}]},{"title":"Baseline temp. 37 - <38°C, on treatment change 1 - <2°C","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Baseline temp. 37 - <38°C, on treatment change 2 - <3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 37 - <38°C, on treatment change >=3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 37 - <38°C, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}]}]},{"title":"Baseline temp. 38 - <39°C, on treatment change <1°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 38 - <39°C, on treatment change 1 - <2°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 38 - <39°C, on treatment change 2 - <3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 38 - <39°C, on treatment change >=3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 38 - <39°C, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 39 - <40°C, on treatment change <1°C","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 39 - <40°C, on treatment change 1 - <2°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 39 - <40°C, on treatment change 2 - <3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 39 - <40°C, on treatment change >=3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. 39 - <40°C, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. >=40°C, on treatment change <1°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. >=40°C, on treatment change 1 - <2°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. >=40°C, on treatment change 2 - <3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. >=40°C, on treatment change >=3°C","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. >=40°C, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline temp. missing, on treatment change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease","description":"The number of participants with maximal on-treatment changes from baseline in Increase (Ic.)/Decrease (Dc.) in maximal weight were reported by using criteria: Ic./Dc. From baseline, on treatment (TR) change \\<10 percentage (%), \\>=10% and missing.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Ic. from baseline, on TR change <10%","categories":[{"measurements":[{"groupId":"OG000","value":"302"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"436"}]}]},{"title":"Ic. from baseline, on TR change >=10%","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"39"}]}]},{"title":"Ic. from baseline, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"25"}]}]},{"title":"Dc. from baseline, on TR change <10%","categories":[{"measurements":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"258"},{"groupId":"OG002","value":"423"}]}]},{"title":"Dc. from baseline, on TR change >=10%","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"52"}]}]},{"title":"Dc. from baseline, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"25"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease","description":"The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) heart rate (HR) (beats per minute \\[bpm\\]) were reported by using criteria: Ic./Dc. BS HR \\<100/\\>=100 bpm, on treatment change =\\<20 bpm, \\>20 - =\\<40 bpm, \\>40 bpm and missing; Ic./Dc. BS HR missing, on treatment change missing.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Ic. BS HR <100 bpm, on TR change =<20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"332"}]}]},{"title":"Ic. BS HR <100 bpm, on TR change >20 - =<40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"85"}]}]},{"title":"Ic. BS HR <100 bpm, on TR change >40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"9"}]}]},{"title":"Ic. BS HR <100 bpm, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"16"}]}]},{"title":"Ic. BS HR >= 100 bpm, on TR change =<20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"46"}]}]},{"title":"Ic. BS HR >= 100 bpm, on TR change >20 - =<40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]},{"title":"Ic. BS HR >= 100 bpm, on TR change >40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Ic. BS HR >= 100 bpm, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"}]}]},{"title":"Ic. BS HR missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Dc. BS HR <100 bpm, on TR change =<20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"227"},{"groupId":"OG002","value":"385"}]}]},{"title":"Dc. BS HR <100 bpm, on TR change >20 - =<40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"40"}]}]},{"title":"Dc. BS HR <100 bpm, on TR change >40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Dc. BS HR <100 bpm, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"16"}]}]},{"title":"Dc. BS HR >= 100 bpm, on TR change =<20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"20"}]}]},{"title":"Dc. BS HR >= 100 bpm, on TR change >20 - =<40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"26"}]}]},{"title":"Dc. BS HR >= 100 bpm, on TR change >40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}]}]},{"title":"Dc. BS HR >= 100 bpm, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"}]}]},{"title":"Dc. BS HR missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease","description":"The number of participants with maximal on-treatment changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) Systolic Blood Pressure (SBP) and diastolic blood pressure (DBP) (millimeter of mercury \\[mmHg\\]) were reported by using criteria: Ic./Dc. BS SBP \\<140 mmHg and \\>=140 mmHg, on maximal treatment (TR) change =\\<20 mmHg, \\>20 - =\\<40 mmHg, \\>40 mmHg and missing; Ic./Dc. BS SBP missing, on maximal treatment (TR) change missing; Ic./Dc. BS DBP \\<90 mmHg and \\>= 90 mmHg, on maximal TR change =\\<20 mmHg, \\>20 - =\\<40 mmHg, \\>40 mmHg and missing; Ic./Dc. BS DBP missing on maximal TR change missing.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Ic. BS SBP <140 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"209"},{"groupId":"OG002","value":"278"}]}]},{"title":"Ic. BS SBP <140 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"104"}]}]},{"title":"Ic. BS SBP <140 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"10"}]}]},{"title":"Ic. BS SBP <140 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"}]}]},{"title":"Ic. BS SBP >=140 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"78"}]}]},{"title":"Ic. BS SBP >=140 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}]},{"title":"Ic. BS SBP >=140 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Ic. BS SBP > = 140 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Ic. BS SBP missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Dc. BS SBP <140 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"204"},{"groupId":"OG002","value":"322"}]}]},{"title":"Dc. BS SBP <140 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"69"}]}]},{"title":"Dc. BS SBP <140 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}]}]},{"title":"Dc. BS SBP <140 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"}]}]},{"title":"Dc. BS SBP >=140 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"32"}]}]},{"title":"Dc. BS SBP >=140 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"34"}]}]},{"title":"Dc. BS SBP >=140 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"18"}]}]},{"title":"Dc. BS SBP > = 140 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Dc. BS SBP missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Ic. BS DBP <90 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"260"},{"groupId":"OG002","value":"402"}]}]},{"title":"Ic. BS DBP <90 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"45"}]}]},{"title":"Ic. BS DBP <90 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Ic. BS DBP <90 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"23"}]}]},{"title":"Ic. BS DBP missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Ic. BS DBP >=90 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"28"}]}]},{"title":"Ic. BS DBP >=90 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Ic. BS DBP >=90 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Ic. BS DBP >=90 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Dc. BS DBP <90 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"415"}]}]},{"title":"Dc. BS DBP <90 mmHg, on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"32"}]}]},{"title":"Dc. BS DBP <90 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Dc. BS DBP <90 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"23"}]}]},{"title":"Dc. BS DBP >=90 mmHg, on TR change =<20 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"18"}]}]},{"title":"Dc. BS DBP >=90 mmHg,on TR change >20 - =<40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}]}]},{"title":"Dc. BS DBP >=90 mmHg, on TR change >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Dc. BS DBP >=90 mmHg, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Dc. BS DBP missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease","description":"The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) maximal Respiration Rate (RR) were reported by using criteria: Ic./Dc. BS RR \\<20 breaths per minute (breaths/min), on TR change =\\<5 breaths/min, \\>5 - =\\<10 breaths/min, \\>10 breaths/min and missing. Ic./Dc. BS RR missing, on TR change missing. Ic./Dc. BS RR \\>=20 breaths/min, on TR change =\\<5 breaths/min, \\>5 - =\\<10 breaths/min, \\>10 breaths/min and missing.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Ic. BS RR <20 breaths/min, on TR change =<5 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"224"},{"groupId":"OG002","value":"306"}]}]},{"title":"Ic.BS RR<20 breaths/min, on TR change >5 - = <10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"26"}]}]},{"title":"Ic. BS RR <20 breaths/min, on TR change >10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"Ic. BS RR <20 breaths/min, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"14"}]}]},{"title":"Ic. BS RR >=20 breaths/min, on TR change =<5 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"124"}]}]},{"title":"Ic.BS RR >=20 breaths/min, on TR change >5 - =<10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]},{"title":"Ic. BS RR >=20 breaths/min, on TR change >10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Ic. BS RR >=20 breaths/min, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"}]}]},{"title":"Ic. BS RR missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"}]}]},{"title":"Dc. BS RR <20 breaths/min, on TR change =<5 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"325"}]}]},{"title":"Dc. BS RR <20 breaths/min, on TR change >5 - =<10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"}]}]},{"title":"Dc. BS RR <20 breaths/min, on TR change >10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Dc. BS RR <20 breaths/min, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"14"}]}]},{"title":"Dc. BS RR >=20 breaths/min, on TR ch =<5 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"101"}]}]},{"title":"Dc.BS RR >=20 breaths/min, on TR change >5 - =<10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"22"}]}]},{"title":"Dc. BS RR >=20 breaths/min, on TR change >10 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]},{"title":"Dc. BS RR >=20 breaths/min, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"}]}]},{"title":"Dc. BS RR missing, on TR change missing","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters","description":"ECG parameters included heart rate, PR interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). PCSA criteria for abnormal value of ECG parameters: any heart rate \\<= 50 bpm and decrease from baseline \\>=20 bpm , any hear rate \\>= 120 bpm and increase from baseline \\>= 20 bpm; PR interval: \\>= 220 milliseconds (ms) and increase from baseline \\>= 20 ms; QRS interval \\>= 120 ms; QTcF \\> 450 ms, \\> 480 ms, \\> 500 ms, QTcF increase from baseline \\> 30 ms and QTcF increase from baseline \\> 60 ms; QTcB \\> 450 ms, \\> 480 ms, \\> 500 ms, QTcB increase from baseline \\> 30 ms and QTcB increase from baseline \\> 60 ms.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"223"},{"groupId":"OG002","value":"399"}]}],"classes":[{"title":"Heart Rate <= 50 bpm and decrease from baseline >= 20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Heart Rate >= 120 bpm and decrease from baseline >= 20 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"PR interval >= 220 ms and increase from baseline >= 20 ms","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}]}]},{"title":"QRS interval >= 120 ms","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"}]}]},{"title":"QTcF > 450 ms","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"24"}]}]},{"title":"QTcF > 480 ms","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"11"}]}]},{"title":"QTcF > 500 ms","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"}]}]},{"title":"QTcF increase from baseline > 30 ms","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"39"}]}]},{"title":"QTcF increase from baseline > 60 ms","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"}]}]},{"title":"QTcB > 450 ms","categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"70"}]}]},{"title":"QTcB > 480 ms","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"24"}]}]},{"title":"QTcB > 500 ms","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"16"}]}]},{"title":"QTcB increase from baseline > 30 ms","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"49"}]}]},{"title":"QTcB increase from baseline > 60 ms","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"19"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score","description":"ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with baseline value vs worst post-baseline value (that is \\[i.e.\\] highest score).","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab or chemotherapy.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"318"},{"groupId":"OG002","value":"500"}]}],"classes":[{"title":"Baseline score 0, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"84"}]}]},{"title":"Baseline score 0, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"83"}]}]},{"title":"Baseline score 0, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"}]}]},{"title":"Baseline score 0, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}]},{"title":"Baseline score 0, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score 0, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Baseline score 0, worst post-baseline score Missing","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}]},{"title":"Baseline score 1, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}]}]},{"title":"Baseline score 1, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"233"}]}]},{"title":"Baseline score 1, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"46"}]}]},{"title":"Baseline score 1, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"6"}]}]},{"title":"Baseline score 1, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}]},{"title":"Baseline score 1, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"Baseline score 1, worst post-baseline score Missing","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"16"}]}]},{"title":"Baseline score >=2, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score >=2, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Baseline score missing, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Baseline score missing, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab","description":"Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay were tested for neutralizing antibodies (nAb). Number of participants with ADA or nAb positive results for Avelumab were reported.","populationDescription":"The Safety analysis set (Safety-AS) included all randomized participants who were administered at least one dose of the study medication, that is (i.e.) avelumab. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","groups":[{"id":"OG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities."},{"id":"OG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"318"}]}],"classes":[{"title":"ADAs to Avelumab","categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"38"}]}]},{"title":"NAbs to Avelumab","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"18"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","description":"Only participants who received study medication were included in the analysis of adverse events. All randomized participants were included in the analysis of all-cause mortality.","eventGroups":[{"id":"EG000","title":"Avelumab Biweekly","description":"Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.","deathsNumAffected":279,"deathsNumAtRisk":366,"seriousNumAffected":181,"seriousNumAtRisk":361,"otherNumAffected":331,"otherNumAtRisk":361},{"id":"EG001","title":"Avelumab Weekly","description":"Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks, followed by Avelumab at a dose of 10 mg/kg once every 2 weeks until disease progression or unacceptable toxicities.","deathsNumAffected":237,"deathsNumAtRisk":322,"seriousNumAffected":143,"seriousNumAtRisk":318,"otherNumAffected":298,"otherNumAtRisk":318},{"id":"EG002","title":"Chemotherapy","description":"Participants with tumor of nonsquamous histology received Pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) in combination with Cisplatin (75 mg/m\\^2) administered on Day 1 of each cycle or pemetrexed (500 mg/m\\^2) in combination with carboplatin (area under the concentration curve \\[AUC\\] 6 milligrams per milliliter \\[mg/mL\\] \\* minutes \\[min\\] administered on Day 1 of each cycle). Participants who were assigned pemetrexed could continue to receive pemetrexed as a maintenance therapy after 4 cycles of platinum-based chemotherapy if their disease had not progressed, or in accordance with pemetrexed local label. Participants with tumor of squamous histology received Paclitaxel (200 mg/m\\^2) plus carboplatin (AUC 6 mg/mL \\* min administered on Day 1 of each cycle) or Gemcitabine (1250 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus cisplatin (75 mg/m\\^2) or Gemcitabine (1000 mg/m\\^2 administered on Day 1 and Day 8 of each cycle) plus carboplatin (AUC 5 mg/mL \\* min) in 3-week cycles up to a maximum of 6 cycles of IV injection or until disease progression or unacceptable toxicities.","deathsNumAffected":405,"deathsNumAtRisk":526,"seriousNumAffected":195,"seriousNumAtRisk":500,"otherNumAffected":474,"otherNumAtRisk":500}],"seriousEvents":[{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":7,"numAtRisk":500}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":6,"numAtRisk":500}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":4,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":4,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":361},{"groupId":"EG001","numAffected":13,"numAtRisk":318},{"groupId":"EG002","numAffected":28,"numAtRisk":500}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":6,"numAtRisk":500}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":361},{"groupId":"EG001","numAffected":18,"numAtRisk":318},{"groupId":"EG002","numAffected":22,"numAtRisk":500}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":5,"numAtRisk":500}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":361},{"groupId":"EG001","numAffected":7,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":4,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":9,"numAtRisk":500}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":7,"numAtRisk":500}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":19,"numAtRisk":500}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":13,"numAtRisk":500}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":6,"numAtRisk":500}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":7,"numAtRisk":500}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":5,"numAtRisk":500}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Idiopathic pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Stridor","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Respiratory depression","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Amoebiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Device related sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Enterobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Nosocomial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Perirectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Pseudomonal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Sepsis syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Systemic candida","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Sudden cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Post procedural discomfort","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Spinal cord injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Radiation necrosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Large intestinal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Mechanical ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Autoimmune colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Incarcerated inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Inflammatory bowel disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Ventricle rupture","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cardiac hypertrophy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Toxic cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Brachial plexopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Myasthenic syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Laryngeal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Lymphangiosis carcinomatosa","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Squamous cell carcinoma of the oral cavity","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Duodenal neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Malignant ascites","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Metastases to lymph nodes","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Seborrhoeic keratosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Tumor compression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Tumor hemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Tumor pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Peripheral ischemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Shock hemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Inferior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Peripheral artery stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Crystal arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Muscle twitching","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Dermatitis exfoliative generalized","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Lichenoid keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Haematotoxicity","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Goiter","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Immune-mediated hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cytokine release syndrome","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Biliary obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hepatitis toxic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Breath holding","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Macular fibrosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Swelling of eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Aplasia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]}],"otherEvents":[{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":361},{"groupId":"EG001","numAffected":54,"numAtRisk":318},{"groupId":"EG002","numAffected":74,"numAtRisk":500}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":361},{"groupId":"EG001","numAffected":56,"numAtRisk":318},{"groupId":"EG002","numAffected":99,"numAtRisk":500}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":361},{"groupId":"EG001","numAffected":50,"numAtRisk":318},{"groupId":"EG002","numAffected":32,"numAtRisk":500}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":361},{"groupId":"EG001","numAffected":20,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":16,"numAtRisk":500}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":361},{"groupId":"EG001","numAffected":9,"numAtRisk":318},{"groupId":"EG002","numAffected":48,"numAtRisk":500}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":361},{"groupId":"EG001","numAffected":15,"numAtRisk":318},{"groupId":"EG002","numAffected":10,"numAtRisk":500}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":5,"numAtRisk":500}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":361},{"groupId":"EG001","numAffected":50,"numAtRisk":318},{"groupId":"EG002","numAffected":49,"numAtRisk":500}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":361},{"groupId":"EG001","numAffected":41,"numAtRisk":318},{"groupId":"EG002","numAffected":45,"numAtRisk":500}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":361},{"groupId":"EG001","numAffected":23,"numAtRisk":318},{"groupId":"EG002","numAffected":23,"numAtRisk":500}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":361},{"groupId":"EG001","numAffected":8,"numAtRisk":318},{"groupId":"EG002","numAffected":14,"numAtRisk":500}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":11,"numAtRisk":500}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":5,"numAtRisk":500}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":361},{"groupId":"EG001","numAffected":32,"numAtRisk":318},{"groupId":"EG002","numAffected":41,"numAtRisk":500}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":361},{"groupId":"EG001","numAffected":37,"numAtRisk":318},{"groupId":"EG002","numAffected":37,"numAtRisk":500}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":361},{"groupId":"EG001","numAffected":22,"numAtRisk":318},{"groupId":"EG002","numAffected":30,"numAtRisk":500}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":361},{"groupId":"EG001","numAffected":17,"numAtRisk":318},{"groupId":"EG002","numAffected":11,"numAtRisk":500}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":361},{"groupId":"EG001","numAffected":20,"numAtRisk":318},{"groupId":"EG002","numAffected":22,"numAtRisk":500}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":30,"numAtRisk":500}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":361},{"groupId":"EG001","numAffected":17,"numAtRisk":318},{"groupId":"EG002","numAffected":17,"numAtRisk":500}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":361},{"groupId":"EG001","numAffected":10,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":43,"numAtRisk":500}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":62,"numAtRisk":500}]},{"term":"Blood calcium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":39,"numAtRisk":500}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":59,"numAtRisk":361},{"groupId":"EG001","numAffected":21,"numAtRisk":318},{"groupId":"EG002","numAffected":87,"numAtRisk":500}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":361},{"groupId":"EG001","numAffected":33,"numAtRisk":318},{"groupId":"EG002","numAffected":164,"numAtRisk":500}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":361},{"groupId":"EG001","numAffected":39,"numAtRisk":318},{"groupId":"EG002","numAffected":47,"numAtRisk":500}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":361},{"groupId":"EG001","numAffected":24,"numAtRisk":318},{"groupId":"EG002","numAffected":73,"numAtRisk":500}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":16,"numAtRisk":500}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":7,"numAtRisk":500}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":361},{"groupId":"EG001","numAffected":21,"numAtRisk":318},{"groupId":"EG002","numAffected":21,"numAtRisk":500}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":361},{"groupId":"EG001","numAffected":11,"numAtRisk":318},{"groupId":"EG002","numAffected":16,"numAtRisk":500}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":361},{"groupId":"EG001","numAffected":24,"numAtRisk":318},{"groupId":"EG002","numAffected":28,"numAtRisk":500}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":12,"numAtRisk":500}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":361},{"groupId":"EG001","numAffected":9,"numAtRisk":318},{"groupId":"EG002","numAffected":12,"numAtRisk":500}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":361},{"groupId":"EG001","numAffected":14,"numAtRisk":318},{"groupId":"EG002","numAffected":17,"numAtRisk":500}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":361},{"groupId":"EG001","numAffected":61,"numAtRisk":318},{"groupId":"EG002","numAffected":90,"numAtRisk":500}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":361},{"groupId":"EG001","numAffected":20,"numAtRisk":318},{"groupId":"EG002","numAffected":12,"numAtRisk":500}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":361},{"groupId":"EG001","numAffected":16,"numAtRisk":318},{"groupId":"EG002","numAffected":15,"numAtRisk":500}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":361},{"groupId":"EG001","numAffected":10,"numAtRisk":318},{"groupId":"EG002","numAffected":21,"numAtRisk":500}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":26,"numAtRisk":500}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":361},{"groupId":"EG001","numAffected":31,"numAtRisk":318},{"groupId":"EG002","numAffected":31,"numAtRisk":500}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":361},{"groupId":"EG001","numAffected":29,"numAtRisk":318},{"groupId":"EG002","numAffected":34,"numAtRisk":500}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":361},{"groupId":"EG001","numAffected":15,"numAtRisk":318},{"groupId":"EG002","numAffected":11,"numAtRisk":500}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":20,"numAtRisk":500}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":15,"numAtRisk":500}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":361},{"groupId":"EG001","numAffected":6,"numAtRisk":318},{"groupId":"EG002","numAffected":9,"numAtRisk":500}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":12,"numAtRisk":500}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":361},{"groupId":"EG001","numAffected":27,"numAtRisk":318},{"groupId":"EG002","numAffected":36,"numAtRisk":500}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":361},{"groupId":"EG001","numAffected":28,"numAtRisk":318},{"groupId":"EG002","numAffected":15,"numAtRisk":500}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":4,"numAtRisk":500}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":30,"numAtRisk":500}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":1,"numAtRisk":500}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":361},{"groupId":"EG001","numAffected":21,"numAtRisk":318},{"groupId":"EG002","numAffected":24,"numAtRisk":500}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":361},{"groupId":"EG001","numAffected":12,"numAtRisk":318},{"groupId":"EG002","numAffected":29,"numAtRisk":500}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":5,"numAtRisk":500}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":14,"numAtRisk":500}]},{"term":"Taste disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":361},{"groupId":"EG001","numAffected":28,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":361},{"groupId":"EG001","numAffected":57,"numAtRisk":318},{"groupId":"EG002","numAffected":232,"numAtRisk":500}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":42,"numAtRisk":500}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":113,"numAtRisk":500}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":8,"numAtRisk":318},{"groupId":"EG002","numAffected":60,"numAtRisk":500}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":3,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":361},{"groupId":"EG001","numAffected":13,"numAtRisk":318},{"groupId":"EG002","numAffected":20,"numAtRisk":500}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":1,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":361},{"groupId":"EG001","numAffected":13,"numAtRisk":318},{"groupId":"EG002","numAffected":33,"numAtRisk":500}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":2,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":361},{"groupId":"EG001","numAffected":21,"numAtRisk":318},{"groupId":"EG002","numAffected":8,"numAtRisk":500}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":361},{"groupId":"EG001","numAffected":4,"numAtRisk":318},{"groupId":"EG002","numAffected":3,"numAtRisk":500}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":361},{"groupId":"EG001","numAffected":9,"numAtRisk":318},{"groupId":"EG002","numAffected":7,"numAtRisk":500}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":2,"numAtRisk":500}]},{"term":"Vitreous floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Tumor pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":361},{"groupId":"EG001","numAffected":5,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":361},{"groupId":"EG001","numAffected":0,"numAtRisk":318},{"groupId":"EG002","numAffected":0,"numAtRisk":500}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Communication Center","organization":"Merck KGaA, Darmstadt, Germany","email":"service@emdgroup.com","phone":"+49-6151-72-5200"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-01-03","uploadDate":"2022-12-09T02:47","filename":"Prot_000.pdf","size":4653106},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-10-12","uploadDate":"2022-11-07T06:00","filename":"SAP_001.pdf","size":10170647}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Mexico"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000609138","term":"avelumab"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}